Trio of trials supports roxadustat for CKD-anaemia
19 Nov 2019
byElvira Manzano
Roxadustat improves haemoglobin levels vs placebo and epoetin alfa, with similar safety profile, in 8,000 patients with chronic kidney disease (CKD)-related anaemia on- and off-dialysis, according to a pooled efficacy and CV safety analyses of roxadustat, spanning over 13,000 patient exposure years.